Core Viewpoint - Alma Lasers Ltd., a wholly-owned subsidiary of Revance Therapeutics (01696), has entered into a strategic partnership with renowned skincare expert Jamie Sherrill, enhancing its position in the high-end aesthetic technology market [1] Group 1: Strategic Partnership - The collaboration with Jamie Sherrill aims to improve consumer engagement and solidify Alma's leadership in aesthetic technology [1] - Jamie Sherrill will serve as a strategic ambassador for Alma's flagship device platforms, including Alma Harmony and Opus series, leading global promotional activities [1] Group 2: Market Impact - The partnership is expected to increase consumer awareness of Alma's high-end solutions and create stronger demand for global clinic partners [1] - The collaboration is anticipated to open new growth opportunities for the company in the consumer market [1]

Core Viewpoint - Alma Lasers Ltd. has entered into a strategic partnership with renowned skincare expert Jamie Sherrill to enhance consumer engagement and solidify its leadership in high-end aesthetic technology [1] Group 1: Strategic Partnership - The partnership aims to leverage Jamie Sherrill's influence in the aesthetic field to promote Alma's flagship equipment platforms, including Alma Harmony and Opus series [1] - Jamie Sherrill will lead global promotional activities to increase the brand's global recognition and accelerate market penetration of Alma's aesthetic solutions [1] Group 2: Market Impact - The collaboration is expected to enhance consumer awareness of Alma's high-end solutions and create stronger demand for global clinic partners, opening new growth opportunities [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 Sisram Medical Ltd 復䢇醫療科技有限公司* 本公司欣然宣佈，本公司全資附屬公司，專注於能量源醫美設備美學解決方案提 供商，Alma Lasers Ltd.（「Alma」）與國際知名皮膚護理專家、企業家及醫美領域 廣受認可的國際意見領袖Jamie Sherrill（「Nurse Jamie」）達成戰略合作。此次合作 標誌著Alma在提高消費者互動，鞏固其高端美學技術領導地位的戰略部署中邁出 重要一步。 股東及投資者於買賣本公司證券時務請審慎行事。 代表董事會 Sisram Medical Ltd 復銳醫療科技有限公司* 主席 劉毅 Jamie Sherrill是一名專注美學領域的註冊護士，憑藉循證醫學理念和創新治療方 案，在線上擁有廣泛的影 ...

Financial Data and Key Metrics Changes - The company reported revenue of $165.5 million for H1 2025, a decrease of approximately 1.9% compared to the previous year, primarily due to challenging market conditions such as high interest rates and weakened consumer spending in North America [8][14][18] - Gross profit margin was 60%, down 2.4 percentage points year over year, attributed to a shift in product mix towards higher-cost professional products and lower revenue contribution from North America [15][16] - Adjusted net profit was $12 million, reflecting a decline of 28.1% year over year [16] Business Line Data and Key Metrics Changes - Medical aesthetics products remained the largest revenue contributor, generating $137.7 million, or 83.2% of total revenue [16] - The injectables segment saw significant growth, increasing by 280.1% to $14.4 million, representing 8.7% of total revenue, up from 2.7% [16] Market Data and Key Metrics Changes - International sales channels grew by 7.1% year over year, with the Asia Pacific region achieving double-digit growth of 17.6%, driven by strong performance in Thailand and Korea [10][14] - The company’s direct operations worldwide provided robust market access and execution capabilities, allowing it to offset regional challenges [10] Company Strategy and Development Direction - The company is transitioning to a holistic ecosystem partner in medical aesthetics, integrating energy-based devices, injectables, and personalized skincare [4][5] - Future focus includes strengthening corporate leadership in Asia Pacific and North America, with anticipated launches of new products like Dexify in China [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in regaining momentum in regions affected by geopolitical tensions and anticipated stronger performance in H2 2025 due to increased consumer confidence and demand for recent launches [11][12] - The company plans to continue expanding its unique wellness ecosystem and deepen relationships with clinics and end consumers [12] Other Important Information - The successful North American launch of Universe Skin by Alma, an AI-assisted skincare system, is a key milestone for the company [5] - The company is preparing for the launch of Dexify, the world's first peptide-powered botulinum toxin in Mainland China, and expanding its injectable portfolio in various regions [12][15] Q&A Session Summary Question: What is the main reason for the good performance in the APAC area? - Growth in Thailand was driven by the introduction of Profilo, while Korea benefited from existing direct operations and the concept of lifting using titanium [20][22] Question: What is the proportion of direct sales in the first half of the year? - Approximately 85% of the business was from direct operations, slightly down due to a shift towards distributor fulfillment in North America [24][25] Question: What are the main reasons for the decrease in North America performance? - High interest rates and consumer spending concerns led to delays in deal closures and order processing [29][32] Question: What is the current progress of the launch of Dexify in China? - The company is advancing phase three clinical trials for Dexify and expects to launch in H2 2025, aiming for significant sales growth in the following years [55][56] Question: What are the differences among the injectable products? - The company offers a range of injectables including neotoxins, volumetric fillers, and biostimulators, each serving different clinical needs [60][62] Question: What is the guidance on revenue and net profit for 2025? - The company expects growth in both revenue and net profit in the second half of 2025, driven by new product launches and a backlog of orders [70][72]

Financial Performance - Sisram Medical's revenue decreased by 1.9% year-over-year to $165.5 million in H1 2025 [9, 71], but excluding North America, revenue grew 7.1% YoY [71] - Gross profit margin decreased by 2.4 percentage points to 60.0% [9, 71], due to product mix and decreased North America revenue [71] - Injectables revenue increased significantly by 218.1% year-over-year [9, 79], driven by geographical expansion and commercialization efforts [80] - Net profit decreased by 31.9% [70] Regional Performance - North America revenue decreased by 15.6% [10, 75] due to market headwinds [75] - APAC revenue increased by 17.6% [10, 75] due to the "Go-Direct" strategy [75] - Europe revenue declined slightly by 0.8% [75], but new EBD platforms saw notable growth [75] - Middle East and Africa revenue decreased by 9.7% [76] due to geopolitical tensions [76] Strategic Initiatives - The company is preparing for the launch of DAXXIFY in mainland China in H2 2025 [13, 45, 86] - The company is expanding global penetration of Alma Harmony, Alma IQ, and Universkin by Alma [86] - The company is driving injectables portfolio Revanesse and Profhilo growth in key markets [86] - The company is developing direct-sales offices in strategic regions [86]